The full results of the study, conducted by the U.S. government agency National Institute of Allergy and Infectious Diseases (NIAID), were published by the New England Journal of Medicine.
The United States authorized the emergency use of Remdesivir in hospitals on May 1, followed by Japan as Europe considered what to do.
The study found that Remdesivir, injected intravenously daily for 10 days, accelerated the recovery of hospitalized patients with COVID-19 compared with placebo in clinical trials in just over a thousand patients in 10 countries.
On April 29, NIAID Director Anthony Fauci, who became a U.S. government trustee in the coronavirus pandemic, said preliminary evidence showed that Remdesivir had “a clear, significant, and positive effect in reducing recovery time.”
The National Institutes of Health, of which NIAID is a part, said in an online statement on Friday that experts found that Remdesivir was most useful for hospitalized patients with a serious illness who needed extra oxygen.
However, the authors of the study warn that the drug does not prevent all deaths.
“Given the high mortality rate despite the use of Remdesivir, it is clear that antiviral treatment alone may not be sufficient.They said.
About 7.1% of the patients receiving Remdesivir in the trial group died within 14 days, compared with 11.9% in the placebo group.
However, the result is slightly below the threshold of statistical reliability, which means that the effect may be reduced to chance and not to the ability of the drug.